Date: 0201-10-06
Type of information: Distribution agreement
Compound: CRISPR/Cas9 human haploid cell line generation service and human haploid knock-out cell lines catalog
Company: Horizon Discovery (UK) Haplogen Genomics (Austria)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism:
Disease:
Details: * On October 6, 2014, Horizon Discovery Group, a provider of research tools to support translational genomics and the development of personalized medicines,announced it has entered a worldwide co-exclusive distribution agreement with Haplogen Genomics. The agreement provides Horizon with access to a new high-throughput, affordable cell line engineering service. Haplogen’s extensive experience with haploid cell lines, along with a highly optimized production pipeline, allows knockouts for any non-essential gene to be generated at a throughput of hundreds of new isogenic cell lines per month. Horizon will also market Haplogen’s rapidly growing collection of over 700 human knockout cell lines, the largest collection of human cell lines deficient for the expression of single genes available, and more than 9,000 thousand gene trap mutants to the over 70,000 active academic research labs worldwide. Haplogen’s human cell lines carry only a single copy of each of its chromosomes and have been comprehensively characterized at the genomic, transcriptional and functional level, making them ideal for the of study a great variety of biological processes, such as signal transduction, cellular trafficking, DNA repair, cell cycle or host-pathogen interactions.
Financial terms:
Latest news:
